chronic hepatitis C virus infection
Hepatology · 2014–2018
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| grazoprevir with elbasvir Chronic Hepatitis C Virus infection – Genotype 1 or 4 in adults. The submission sought to amend the current listing from Authority Required (In Writing or… | Mar 2018 | Deferred | input received Hepatitis Australia |
| sofosbuvir with velpatasvir Treatment of chronic hepatitis C virus infection, genotypes 1, 2, 3, 4, 5 or 6 (all genotypes). | Jul 2017 | Noted | none received |
| paritaprevir / ritonavir / ombitasvir Treatment of genotype 4 chronic hepatitis C infection in treatment-naive and treatment-experienced patients, irrespective of cirrhotic status, in combination… | Nov 2016 | Recommended with restriction | 3 individuals Hepatitis Australia · Haemophilia Foundation Australia · Haymarket Foundation · Paul Society |
| sofosbuvir with velpatasvir Treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes 1-6, with or without cirrhosis. | Nov 2016 | Recommended with restriction | 3 individuals Hepatitis Australia · Haemophilia Foundation Australia · Haymarket Foundation · Paul Society |
| daclatasvir Treatment of chronic hepatitis C virus (HCV) infection in combination with sofosbuvir for genotype 1 (treatment-naïve, non-cirrhotic) and genotype 3 patients. | Mar 2015 | Recommended with restriction | 172 individuals Gastroenterological Society of Australia |
| simeprevir Chronic genotype 1 hepatitis C virus infection, in treatment-naïve patients or patients previously treated with interferon alfa or peginterferon alfa, in… | Jul 2014 | Recommended with restriction | 261 individuals |
Who spoke
Hepatitis Australia · Haemophilia Foundation Australia · Haymarket Foundation · Paul Society · Gastroenterological Society of Australia
What the PBS pays
$157M in government benefit over 2024–25, across 11,586 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sofosbuvir with velpatasvir | $156.9M |
| paritaprevir with ritonavir and ombitasvir | $0.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.